Clinical resistance to antitumour drugs has been recognised in patients who have received radiotherapy as well as in those treated with chemotherapy. To investigate this phenomenon we developed an experimental model system involving the in vitro exposure of mammalian tumour cells to fractionated X-irradiation and have characterised the resistance phenotype expressed. Following irradiation, tumour cells characteristically proved resistant to the Vinca alkaloids and to the epipodophyllotoxins, but not to the anthracyclines. This pattern was observed in a range of tumour cells of both rodent and human origin. Further examination, using irradiated Chinese hamster ovary cells identified modified accumulation of vincristine and overexpression of a functional P-glycoprotein. Construction of intraspecies hybrids revealed that this resistance phenotype was dominantly expressed. Unexpectedly, however, P-glycoprotein overexpression occurred without any concomitant increase in P-glycoprotein messenger RNA. A comparison of the rate of turnover of P-glycoprotein in these irradiated sublines, with that in the classic multidrug-resistant colchicine-selected CHRC5 cells provided evidence of a significantly prolonged half-life of P-glycoprotein in the tumour cells previously exposed to X-irradiation. Therefore, these data not only provide the first evidence that P-glycoprotein expression can be influenced by exposure to X-rays but also the first detailed example of P-glycoprotein being regulated by a posttranslational increased stability. More recent data have confirmed the existence of this same distinctive multiple drug resistance phenotype in sublines of human ovarian tumour cells similarly exposed in vitro to a series of fractions of X-irradiation. If these results are confirmed, and extended to include other tumour types, they provide a clear rationale for monitoring tumour biopsies for P-glycoprotein-associated drug resistance in patients treated with radiotherapy and evaluating protein levels rather than, or as well as, MDR1 messenger RNA expression.

Keywords:
P-glycoprotein, Fractionated X-irradiation, Drug resistance, Tumour cell lines
This content is only available via PDF.
© 1996 S. Karger AG, Basel
1996
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.